Moderna (MRNA): Q1 2026 Earnings Preview – Revenue Doubling and Pipeline Progress in Focus
Key Takeaways
- Analysts expect Q1 2026 revenue of around $224 million, a significant increase from $108 million in Q1 2025.
- Consensus EPS forecast points to a loss of approximately $2.29 per share, potentially improved from prior quarters.
- Investors will watch updates on mRNA pipeline progress, including respiratory vaccines and oncology programs.
- Company reiterated 2026 revenue growth target of up to 10% over 2025's $1.9 billion.
- Historical earnings beats have led to mixed stock reactions, with volatility around guidance.
Earnings Context and Why It Matters
Moderna (MRNA)'s Q1 2026 earnings, due out on May 1 before the market opens, mark a key moment in the company's shift from COVID-19 reliance to a broader mRNA platform. After full-year 2025 revenue of $1.9 billion—down from pandemic highs—Moderna beat Q4 estimates with $678 million in sales and EPS of -$2.11. From what I see, this report serves as an important checkpoint for cost controls, international expansion, and pipeline milestones in flu, RSV, and cancer therapies. Strong execution could point to sustainable growth amid biotech competition, shaping sentiment ahead of respiratory vaccine launches.
Earnings Expectations
Wall Street looks for Q1 revenue of $223.5 million, more than doubling year-over-year from Q1 2025's $108 million, fueled by seasonal vaccine demand and grants. The EPS consensus is a loss of $2.29 per share, narrower than recent quarters thanks to reduced operating expenses.
Focus areas include net product sales from Spikevax, R&D spending, and cash position. The company has a history of EPS beats, such as the $0.51 surprise in Q4 2025, though revenue surprises have been smaller. Updates on 2026 full-year revenue guidance—up to 10% growth—and pipeline readouts will be essential. I also checked MRNA using Tickeron’s AI Screener to compare it against industry peers. Stock reactions to past reports highlight volatility, with gains on beats but sensitivity to forward guidance.
Market Reaction and Investor Sentiment
Heading into earnings, sentiment around MRNA feels cautiously optimistic, lifted by Q4 beats and 2026 growth guidance, yet checked by biotech sector headwinds and vaccine demand uncertainty. Options pricing points to a potential 9% stock move post-report, in line with historical patterns. Risks center on softer sales or approval delays, while narrower losses and positive pipeline news could drive upside. One thing that stands out to me is how guidance often sways the reaction more than the numbers themselves.
A Tool I Use for Analysis: Tickeron’s AI Screener
In my research, I often turn to Tickeron’s AI Screener, an AI-powered tool for discovering stocks and ETFs. It lets me filter thousands of assets using technical patterns, fundamentals, trends, volatility, and AI signals—customized by industry, market cap, indicators, and more. This helps spot trade ideas, trending names, breakouts, and opportunities far faster than manual scans, which is how I evaluated MRNA's positioning. I find it enhances my workflow for earnings previews like this one.
Forward Outlook and Key Factors to Monitor
After earnings, eyes will turn to Moderna's reiterated 2026 guidance: up to 10% revenue growth over 2025, with contributions from U.S. and international respiratory vaccines like next-gen COVID/flu combos. Cost-saving efforts, including GAAP operating expense reductions, are crucial for improving margins.
Pipeline catalysts remain prominent, such as potential approvals for mRNA-1010 flu vaccine in late 2026/early 2027 and oncology updates like mRNA-4157 personalized cancer therapy. I’m watching R&D progress, cash burn—with a solid runway—and demand for the Spikevax 2025-2026 formula. For trends, Tickeron’s AI Trend Prediction Engine offers useful insights into MRNA's momentum.
Broader factors include competition from Pfizer/BioNTech and regulatory paths for rare diseases. In my view, balanced progress here could set Moderna on track for cash breakeven by 2028.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
MRNA in downward trend: price dove below 50-day moving average on May 13, 2026
MRNA moved below its 50-day moving average on May 13, 2026 date and that indicates a change from an upward trend to a downward trend. In of 30 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day moving average for MRNA crossed bearishly below the 50-day moving average on April 29, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRNA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for MRNA entered a downward trend on April 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where MRNA's RSI Indicator exited the oversold zone, of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 60 cases where MRNA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on May 08, 2026. You may want to consider a long position or call options on MRNA as a result. In of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for MRNA just turned positive on May 08, 2026. Looking at past instances where MRNA's MACD turned positive, the stock continued to rise in of 41 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MRNA advanced for three days, in of 279 cases, the price rose further within the following month. The odds of a continued upward trend are .
MRNA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. MRNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.701) is normal, around the industry mean (32.515). P/E Ratio (0.000) is within average values for comparable stocks, (51.289). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.692). Dividend Yield (0.000) settles around the average of (0.033) among similar stocks. P/S Ratio (8.953) is also within normal values, averaging (337.706).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of transformative medicines for patients
Industry Biotechnology
Advertisement